Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Long-term outcomes in young patients with atrioventricular block of unknown aetiology

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Dideriksen, JR, Christiansen, MK, Johansen, JB, Nielsen, JC, Bundgaard, H & Jensen, HK 2021, 'Long-term outcomes in young patients with atrioventricular block of unknown aetiology', European Heart Journal, vol. 42, no. 21, pp. 2060-2068. https://doi.org/10.1093/eurheartj/ehab060

APA

Dideriksen, J. R., Christiansen, M. K., Johansen, J. B., Nielsen, J. C., Bundgaard, H., & Jensen, H. K. (2021). Long-term outcomes in young patients with atrioventricular block of unknown aetiology. European Heart Journal, 42(21), 2060-2068. https://doi.org/10.1093/eurheartj/ehab060

CBE

MLA

Vancouver

Author

Dideriksen, Johnni Resdal ; Christiansen, Morten K ; Johansen, Jens B ; Nielsen, Jens C ; Bundgaard, Henning ; Jensen, Henrik K. / Long-term outcomes in young patients with atrioventricular block of unknown aetiology. In: European Heart Journal. 2021 ; Vol. 42, No. 21. pp. 2060-2068.

Bibtex

@article{4291831506974c758c8922923d30f941,
title = "Long-term outcomes in young patients with atrioventricular block of unknown aetiology",
abstract = "AIMS: Atrioventricular block (AVB) of unknown aetiology is rare in the young, and outcome in these patients is unknown. We aimed to assess long-term morbidity and mortality in young patients with AVB of unknown aetiology.METHODS AND RESULTS: We identified all Danish patients younger than 50 years receiving a first pacemaker due to AVB between January 1996 and December 2015. By reviewing medical records, we included patients with AVB of unknown aetiology. A matched control cohort was established. Follow-up was performed using national registries. The primary outcome was a composite endpoint consisting of death, heart failure hospitalization, ventricular tachyarrhythmia, and cardiac arrest with successful resuscitation. We included 517 patients, and 5170 controls. Median age at first pacemaker implantation was 41.3 years [interquartile range (IQR) 32.7-46.2 years]. After a median follow-up of 9.8 years (IQR 5.7-14.5 years), the primary endpoint had occurred in 14.9% of patients and 3.2% of controls [hazard ratio (HR) 3.8; 95% confidence interval (CI) 2.9-5.1; P < 0.001]. Patients with persistent AVB at time of diagnosis had a higher risk of the primary endpoint (HR 10.6; 95% CI 5.7-20.0; P < 0.001), and risk was highest early in the follow-up period (HR 6.8; 95% CI 4.6-10.0; P < 0.001, during 0-5 years of follow-up).CONCLUSION: Atrioventricular block of unknown aetiology presenting before the age of 50 years and treated with pacemaker implantation was associated with a three- to four-fold higher rate of the composite endpoint of death or hospitalization for heart failure, ventricular tachyarrhythmia, or cardiac arrest with successful resuscitation. Patients with persistent AVB were at higher risk. These findings warrant improved follow-up strategies for young patients with AVB of unknown aetiology.",
keywords = "Atrioventricular block, Follow-up, Long-term outcomes, Pacemaker implantation, Unknown aetiology, Young",
author = "Dideriksen, {Johnni Resdal} and Christiansen, {Morten K} and Johansen, {Jens B} and Nielsen, {Jens C} and Henning Bundgaard and Jensen, {Henrik K}",
note = "{\textcopyright} The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.",
year = "2021",
month = jun,
day = "1",
doi = "10.1093/eurheartj/ehab060",
language = "English",
volume = "42",
pages = "2060--2068",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "21",

}

RIS

TY - JOUR

T1 - Long-term outcomes in young patients with atrioventricular block of unknown aetiology

AU - Dideriksen, Johnni Resdal

AU - Christiansen, Morten K

AU - Johansen, Jens B

AU - Nielsen, Jens C

AU - Bundgaard, Henning

AU - Jensen, Henrik K

N1 - © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

PY - 2021/6/1

Y1 - 2021/6/1

N2 - AIMS: Atrioventricular block (AVB) of unknown aetiology is rare in the young, and outcome in these patients is unknown. We aimed to assess long-term morbidity and mortality in young patients with AVB of unknown aetiology.METHODS AND RESULTS: We identified all Danish patients younger than 50 years receiving a first pacemaker due to AVB between January 1996 and December 2015. By reviewing medical records, we included patients with AVB of unknown aetiology. A matched control cohort was established. Follow-up was performed using national registries. The primary outcome was a composite endpoint consisting of death, heart failure hospitalization, ventricular tachyarrhythmia, and cardiac arrest with successful resuscitation. We included 517 patients, and 5170 controls. Median age at first pacemaker implantation was 41.3 years [interquartile range (IQR) 32.7-46.2 years]. After a median follow-up of 9.8 years (IQR 5.7-14.5 years), the primary endpoint had occurred in 14.9% of patients and 3.2% of controls [hazard ratio (HR) 3.8; 95% confidence interval (CI) 2.9-5.1; P < 0.001]. Patients with persistent AVB at time of diagnosis had a higher risk of the primary endpoint (HR 10.6; 95% CI 5.7-20.0; P < 0.001), and risk was highest early in the follow-up period (HR 6.8; 95% CI 4.6-10.0; P < 0.001, during 0-5 years of follow-up).CONCLUSION: Atrioventricular block of unknown aetiology presenting before the age of 50 years and treated with pacemaker implantation was associated with a three- to four-fold higher rate of the composite endpoint of death or hospitalization for heart failure, ventricular tachyarrhythmia, or cardiac arrest with successful resuscitation. Patients with persistent AVB were at higher risk. These findings warrant improved follow-up strategies for young patients with AVB of unknown aetiology.

AB - AIMS: Atrioventricular block (AVB) of unknown aetiology is rare in the young, and outcome in these patients is unknown. We aimed to assess long-term morbidity and mortality in young patients with AVB of unknown aetiology.METHODS AND RESULTS: We identified all Danish patients younger than 50 years receiving a first pacemaker due to AVB between January 1996 and December 2015. By reviewing medical records, we included patients with AVB of unknown aetiology. A matched control cohort was established. Follow-up was performed using national registries. The primary outcome was a composite endpoint consisting of death, heart failure hospitalization, ventricular tachyarrhythmia, and cardiac arrest with successful resuscitation. We included 517 patients, and 5170 controls. Median age at first pacemaker implantation was 41.3 years [interquartile range (IQR) 32.7-46.2 years]. After a median follow-up of 9.8 years (IQR 5.7-14.5 years), the primary endpoint had occurred in 14.9% of patients and 3.2% of controls [hazard ratio (HR) 3.8; 95% confidence interval (CI) 2.9-5.1; P < 0.001]. Patients with persistent AVB at time of diagnosis had a higher risk of the primary endpoint (HR 10.6; 95% CI 5.7-20.0; P < 0.001), and risk was highest early in the follow-up period (HR 6.8; 95% CI 4.6-10.0; P < 0.001, during 0-5 years of follow-up).CONCLUSION: Atrioventricular block of unknown aetiology presenting before the age of 50 years and treated with pacemaker implantation was associated with a three- to four-fold higher rate of the composite endpoint of death or hospitalization for heart failure, ventricular tachyarrhythmia, or cardiac arrest with successful resuscitation. Patients with persistent AVB were at higher risk. These findings warrant improved follow-up strategies for young patients with AVB of unknown aetiology.

KW - Atrioventricular block

KW - Follow-up

KW - Long-term outcomes

KW - Pacemaker implantation

KW - Unknown aetiology

KW - Young

UR - http://www.scopus.com/inward/record.url?scp=85107710548&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehab060

DO - 10.1093/eurheartj/ehab060

M3 - Journal article

C2 - 33599276

VL - 42

SP - 2060

EP - 2068

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 21

ER -

ID: 62374734